Founders building a device for both the U.S. and European markets used to treat regulatory strategy as a sequencing question: clear FDA first, then adapt the file for CE marking, or the reverse. That assumption is getting more expensive to hold. A 2026 comparative analysis found that having FDA 510(k) clearance does not translate into CE marking under EU MDR, because MDR demands significantly more in clinical evaluation, post-market surveillance and technical documentation than 510(k) requires. RegAid
Intertek's March 2026 analysis put it directly: both frameworks share a patient-safety mission, but the path to compliance diverges sharply in evidence requirements, review structure and lifecycle burden, and companies that assume equivalence between the two are the ones who get stuck. Intertek
Where do the two frameworks actually differ?
| Dimension | FDA 510(k) | EU MDR CE marking |
|---|---|---|
| Core test | Substantial equivalence to a predicate | Conformity with general safety and performance requirements |
| Clinical evidence bar | Often bench testing plus retrospective data | Structured clinical evaluation, often requiring prospective data |
| Review body | FDA directly | Notified Body, a third-party certification organization |
| Post-market requirements | Post-market surveillance, less prescriptive | Extensive post-market clinical follow-up, mandatory |
| Typical timeline | Historically faster for lower-risk devices | Often slower, Notified Body capacity constrained |
The most consequential difference for a founder building a device roadmap is the clinical evidence bar. A 510(k) clearance can, for many Class II devices, rest on non-clinical bench testing and comparison to a predicate. MDR's clinical evaluation requirement is structurally closer to a prospective evidence standard for many device classes, particularly implantable and higher-risk devices, and it explicitly requires ongoing post-market clinical follow-up, not just a one-time submission.
Why is this getting worse, not better, in 2026?
A March 2026 academic analysis in the European Journal of Law and Economics examined regulatory delays and patent term erosion across both markets, finding that the compounding effect of longer EU review timelines is now measurably eating into the commercially useful life of device patents for companies that file in Europe after already filing in the U.S. Springer Notified Body capacity has been a persistent bottleneck since MDR's transition period, and companies now routinely report multi-month to multi-year queues simply to get an initial review slot, independent of how quickly their technical file itself could be assessed.
What should this change about sequencing strategy?
File clinical protocols with both markets in mind from day one, not sequentially. A prospective clinical study designed to satisfy MDR's evaluation standard will typically also exceed what 510(k) requires, which means running the MDR-grade study first, even if the initial commercial launch targets the U.S., can save a full second study cycle later.
Budget Notified Body engagement earlier than seems necessary. Given ongoing capacity constraints, companies that wait until their U.S. clearance is in hand before initiating EU conversations are often adding a year or more of pure queue time on top of the review itself.
Treat post-market surveillance as a design requirement, not paperwork. MDR's mandatory post-market clinical follow-up means a device's data collection architecture needs to be built to support ongoing evidence generation from day one, not retrofitted after the CE mark is granted.
The takeaway
Dual-market medtech launches used to be a paperwork sequencing decision. In 2026 they are a clinical trial design decision, made at the earliest stage of product development. The founders who are still treating 510(k) clearance as a stepping stone to an easy CE mark are the ones who will discover, a year into their EU filing, that the two regulators were never asking the same question in the first place.
